Previous 10 | Next 10 |
On Tuesday, shares of up-and-coming biotechs Marinus Pharmaceuticals (NASDAQ: MRNS) , iBio (NYSEMKT: IBIO) , and Arcturus Therapeutics Holdings (NASDAQ: ARCT) fell by 12%, 13%, and 19%, respectively. One common catalyst seems to be the secondary-share issues anno...
Gainers: Curis (CRIS) +335%.Lexicon Pharmaceuticals (LXRX) +97%.Mammoth Energy Services (TUSK) +61%.NeuroMetrix (NURO) +49%.Stitch Fix (SFIX) +45%.IGM Biosciences (IGMS) +38%.Blonder Tongue Laboratories (BDR) +26%.Infinity Pharmaceuticals (INFI) +25%.KLX Energy Services (KLXE) +24%....
iBio (IBIO) is a Texas-based company whose stock is up 496% year to date on investor optimism about its COVID-19 vaccine efforts. IBIO claims to have been involved in several vaccines for such high profile illnesses as H1N1 and Ebola, but the company never commercialized any of its va...
iBio (IBIO) -14.7% PM, priced its earlier announced underwritten public offering of ~29.7M shares for gross proceeds of $35M.Offering expected to close on or about Dec.10, 2020.Underwriters granted a 30-day option to purchase up to ~4.4M additional shares. For further details see:...
BRYAN, Texas, Dec. 08, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced the pricing of its underwritten public offering of approximately 29.7 million...
Meten EdtechX Education Group (METX) -23% on temporary offer allowing warrants to be exercised at a reduced price of $1.40 per share.Obalon Therapeutics (OBLN) -16%.Francesca's Holdings (FRAN) -13% on notice of delisting from NASDAQ, after it files for bankruptcy.SenesTech (SNES) -1...
iBio (IBIO) announces an underwritten public offering of its common stock. Underwriter's 30-day option to purchase up to an additional 15% shares.Net proceeds to be deployed to accelerate development of its biotherapeutic and vaccine candidates, in-licensing of biopharmaceutical assets, ...
iBio (IBIO) announces a public offering of common stock and will use the proceeds to accelerate development of its biotherapeutic and vaccine candidates, in-licensing of biopharmaceutical assets.Proceeds may also go to working capital needs and general corporate purposes.iBio grants a gr...
BRYAN, Texas, Dec. 07, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced an underwritten public offering of its common stock. In addition, iBio has gr...
Palm Beach, FL – December 3, 2020 – Acute myeloid leukemia (AML) is a rare and heterogeneous blood cancer with a poor overall prognosis. It affects predominantly older adults with a median age at diagnosis of 66 years but also includes about 15% of children from birth to 19 ye...
News, Short Squeeze, Breakout and More Instantly...
– The sale of the facility eliminates $13.2M of secured debt – – Completes iBio’s transition to an AI and precision biologics innovation company - SAN DIEGO, June 03, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or th...
2024-05-28 07:30:05 ET Chardan Capital analyst issues BUY recommendation for IBIO on May 28, 2024 05:34AM ET. IBIO was trading at $2.19 at issue of the analyst recommendation. The overall analyst consensus : HOLD. Current analyst recommendations are : 1 - Hold recommenda...
Strengthened cash position with investment by healthcare specialist investors Expanding into cardio-metabolic space through AstralBio collaboration BRYAN, Texas and SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company...